| Ytd | -51.42% | |
| 1y | 54.14% |
| Open | 3.95 | Prev Close | 3.94 | Low | 3.90 | High | 4.14 | Mkt Cap | 76.68M |
| Vol | 1.55K | Avg Vol | 267.23K | EPS | -2.15 | P/E | -1.91 | Forward P/E | N/A |
| Beta | 0.20 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 4.30 | 200-d Avg | 6.52 | 1yr Est | 0.00 |
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical co
Kalaris Therapeutics (NASDAQ: KLRS) stock jumps 18% after releasing expanded Phase 1a data for its A
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreat